Synthesis and studies of thiazolidinedione–isatin hybrids as α-glucosidase inhibitors for management of diabetes

Papers of special note have been highlighted as: • of interest

References

• 1. Kaur R, Dahiya L, Kumar M. Fructose-1,6-bisphosphatase inhibitors: a new valid approach for management of type 2 diabetes mellitus. Eur. J. Med. Chem. 141, 473–505 (2017).
  Medline CASGoogle Scholar
• 2. Wang G, He D, Li X, Li J, Peng Z. Design, synthesis and biological evaluation of novel coumarin thiazole derivatives as α-glucosidase inhibitors. Bioorg. Chem. 65, 167–174 (2016).
  Medline CASGoogle Scholar
• 3. Momose Y, Maekawa T, Odaka H, Ikeda H, Sohda T. Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. 50, 100–111 (2002).
  Medline CASGoogle Scholar
• 4. Hundal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49, 2063–2069 (2000).
  Medline CASGoogle Scholar
• 5. Chiarelli F, Marzio DD. Peroxisome-proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives. Vasc. Health Risk Manag. 4, 297–304 (2008).
  Medline CASGoogle Scholar
• 6. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47, 345–351 (1998).
  Medline CASGoogle Scholar
• 7. Gloster TM, Davies GJ. Glycosidase inhibition: assessing mimicry of the transition state. Org. Biomol. Chem. 8, 305–320 (2010).
  Medline CASGoogle Scholar
• 8. He ZX, Zhou ZW, Yang Y et al. Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 42, 125–138 (2015).
  Medline CASGoogle Scholar
• 9. Nikookar H, Mohammadi-Khanaposhtani M, Imanparast S et al. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents. Bioorg. Chem. 77, 280–286 (2018).
  Medline CASGoogle Scholar
• 10. Kim JH, Cho CW, Kim HY et al. α-Glycosidase inhibition by prenylated and lavandulyl compounds from Sophora flavescens roots and in silico analysis. Int. J. Biol. Macromol. 102, 960–969 (2017).
  Medline CASGoogle Scholar
• 11. Kazmi M, Zaib S, Ibrar A et al. A new entry into the portfolio of α-glucosidase inhibitors as potent therapeutics for type 2 diabetes: design, bioevaluation and one-pot multi-component synthesis of diamine-bridged coumarinyl oxadiazole conjugates. Bioorg. Chem. 77, 190–202 (2018).
  Medline CASGoogle Scholar
• 12. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur. J. Clin. Invest. 24, 3–10 (1994).
  Medline CASGoogle Scholar
• 13. Ryu HW, Cho JK, Curtis-Long MJ et al. α-Glucosidase inhibition and antihyperglycemic activity of prenylated xanthones from Garcinia mangostana. Phytochemistry 72, 2148–2154 (2011).
  Medline CASGoogle Scholar
• 14. Pascale R, Carocci A, Catalano A et al. New N-(phenoxydecyl)phthalimide derivatives displaying potent inhibition activity towards α-glucosidase. Bioorg. Med. Chem. 18, 5903–5914 (2010).
  Medline CASGoogle Scholar
• 15. Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, Passaniti A. The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55, 2920–2926 (1995). • Highlights the involvement of α-glucosidase in the pathophysiology of various diseases.
  Medline CASGoogle Scholar
• 16. Howe JD, Smith N, Lee MR et al. Novel imino sugar α-glucosidase inhibitors as antiviral compounds. Bioorg. Med. Chem. 21, 4831–4838 (2013). • Highlights the involvement of α-glucosidase in the pathophysiology of various diseases.
  Medline CASGoogle Scholar
• 17. Shimada Y, Nishimura E, Hoshina H et al. Proteasome inhibitor bortezomib enhances the activity of multiple mutant forms of lysosomal α-glucosidase in Pompe disease. JIMD Reports 18, 33–39 (2015). • Highlights the involvement of α-glucosidase in the pathophysiology of Pompe disease.
  MedlineGoogle Scholar
• 18. Hidalgo-Figueroa S, Ramirez-Espinosa JJ, Estrada-Soto S et al. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches. Chem. Biol. Drug Des. 81, 474–483 (2013).
  Medline CASGoogle Scholar
• 19. Kruk I, Bozdag-Dundar O, Ceylan-Unlusoy M, Ertan R, Aboul-Enein HY, Michalska T. Scavenging capacities of some thiazolyl thiazolidine-2,4-dione compounds on superoxide radical, hydroxyl radical, and DPPH radical. Luminescence 24, 230–235 (2009).
  Medline CASGoogle Scholar
• 20. Li QB, Wu JD, Zheng H et al. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. Med. Chem. Lett. 20, 4526–4530 (2010).
  Medline CASGoogle Scholar
• 21. Wang G, Deng C, Xie C et al. Synthesis and biological evaluation of novel dimethyl[1,1′-biphenyl]-2,2′-dicarboxylate derivatives containing thiazolidine-2,4-dione for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. Eur. J. Med. Chem. 46, 5941–5948 (2011). • References 18–21 summarize the biological potential of the TZD nucleus.
  Medline CASGoogle Scholar
• 22. Wang G, Peng Y, Xie Z, Wang J, Chen M. Synthesis, α-glucosidase inhibition and molecular docking studies of novel thiazolidine-2,4-dione or rhodanine derivatives. MedChemComm. 8, 1477–1484 (2017).
  Medline CASGoogle Scholar
• 23. Chinthala Y, Domatti AK, Sarfaraz A et al. Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring. Eur. J. Med. Chem. 70, 308–314 (2013).
  Medline CASGoogle Scholar
• 24. Ibrar A, Zaib S, Khan I et al. New prospects for the development of selective inhibitors of α-glucosidase based on coumarin-iminothiazolidinone hybrids: synthesis, in vitro biological screening and molecular docking analysis. J. Taiwan Inst. Chem. Eng. 81, 119–133 (2017).
  CASGoogle Scholar
• 25. Kaur J, Singh A, Singh G, Verma RK, Mall R. Novel indolyl linked para-substituted benzylidene-based phenyl containing thiazolidienediones and their analogs as α-glucosidase inhibitors: synthesis, in vitro, and molecular docking studies. Med. Chem. Res. 27, 903–914 (2018).
  CASGoogle Scholar
• 26. Senthilkumar N, Vijayakumar V, Sarveswari S, Sarveshwari GA, Gayathri M. Synthesis of new thiazolidine-2,4-dione-azole derivatives and evaluation of their α-amylase and α-glucosidase inhibitory activity. Iran J. Sci. Technol. Trans. Sci. 43, 735–745 (2019). • References 22–26 discuss the α-glucosidase inhibitory potential of TZDs with arylidene scaffold.
  Google Scholar
• 27. Nam NHH, Dung TL, Dung DTM. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Eur. J. Med. Chem. 70, 477–486 (2013).
  Medline CASGoogle Scholar
• 28. Zhang XM, Guo H, Li ZS et al. Synthesis and evaluation of isatin-β-thiosemicarbazones as novel agents against antibiotic-resistant gram-positive bacterial species. Eur. J. Med. Chem. 101, 419–430 (2015).
  Medline CASGoogle Scholar
• 29. Bal TR, Anand B, Yogeeswari P, Sriram D. Synthesis and evaluation of anti-HIV activity of isatin β-thiosemicarbazone derivatives. Bioorg. Med. Chem. Lett. 15, 4451–4455 (2005).
  Medline CASGoogle Scholar
• 30. Zhen X, Peng Z, Zhao S, Han Y, Jin Q, Guan L. Synthesis, potential anticonvulsant and antidepressant effects of 2-(5-methyl-2,3-dioxoindolin-1-yl)acetamide derivatives. Acta Pharm. Sin. B 23, 343–349 (2014).
  Google Scholar
• 31. Sharma PK, Balwani S, Mathur D et al. Synthesis and anti-inflammatory activity evaluation of novel triazolyl-isatin hybrids. J. Enzyme Inhib. Med. Chem. 31, 1520–1526 (2016).
  Medline CASGoogle Scholar
• 32. Raj AA, Raghunathan R, SrideviKumari MR, Raman N. Synthesis, antimicrobial and antifungal activity of a new class of spiro pyrrolidines. Bioorg. Med. Chem. 11, 407–419 (2003). • References 27–32 describe the diverse biological profile of isatin derivatives.
  Medline CASGoogle Scholar
• 33. Rahim F, Malik F, Ullah H et al. Isatin based Schiff bases as inhibitors of α-glucosidase: synthesis, characterization, in vitro evaluation and molecular docking studies. Bioorg. Chem. 60, 42–48 (2015).
  Medline CASGoogle Scholar
• 34. Wang G, Wang J, He D, Li X, Li J, Peng Z. Synthesis, in vitro evaluation and molecular docking studies of novel coumarin-isatin derivatives as α-glucosidase inhibitors. Chem. Biol. Drug Des. 89, 456–463 (2017).
  Medline CASGoogle Scholar
• 35. Xie Z, Wang G, Wang J et al. Synthesis, biological evaluation, and molecular docking studies of novel isatin-thiazole derivatives as α-glucosidase inhibitors. Molecules 22, 659 (2017).
  Google Scholar
• 36. Wang G, Chen M, Qiu J, Xie ZZ, Cao A. Synthesis, in vitro α-glucosidase inhibitory activity and docking studies of novel chromone-isatin derivatives. Bioorg. Med. Chem. Lett. 28, 113–116 (2018).
  Medline CASGoogle Scholar
• 37. Han K, Li Y, Zhang Y et al. Design, synthesis and docking study of novel tetracyclic oxindole derivatives as α-glucosidase inhibitors. Bioorg. Chem. Med. Lett. 25, 1471–1475 (2015). • References 33–37 describe α-glucosidase inhibition studies of isatin derivatives.
  Medline CASGoogle Scholar
• 38. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40, 2004–2021 (2001).
  Medline CASGoogle Scholar
• 39. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov. Today 8, 1128–1137 (2003).
  Medline CASGoogle Scholar
• 40. Tron GC, Pirali T, Billington RA, Canonico PL, Sorba G, Genazzani AA. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med. Res. Rev. 28, 278–308 (2008). • References 38–40 describe the synthesis of triazole nucleus using a click chemistry approach.
  Medline CASGoogle Scholar
• 41. Thomas KD, Adhikari AV, Shetty NS. Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety. Eur. J. Med. Chem. 45, 3803–3810 (2010).
  Medline CASGoogle Scholar
• 42. Manohar S, Khan SI, Rawat DS. Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents. Chem. Biol. Drug Des. 78, 124–136 (2011).
  Medline CASGoogle Scholar
• 43. Kamal A, Shankaraiah N, Devaiah V et al. Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’ chemistry: DNA-binding affinity and anticancer activity. Bioorg. Med. Chem. Lett. 18, 1468–1473 (2008).
  Medline CASGoogle Scholar
• 44. Lazrek HB, Taourirte M, Oulih T et al. Synthesis and anti-HIV activity of new modified 1,2,3-triazole acyclonucleosides. Nucleosides Nucleotides Nucleic Acids 20, 1949–1960 (2001).
  Medline CASGoogle Scholar
• 45. Boechat N, Ferreira VF, Ferreira SB et al. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain. J. Med. Chem. 54, 5988–5999 (2011).
  Medline CASGoogle Scholar
• 46. Iqbal S, Khan MA, Javaid K et al. New carbazole linked 1,2,3-triazoles as highly potent non-sugar α-glucosidase inhibitors. Bioorg. Chem. 74, 72–81 (2017).
  Medline CASGoogle Scholar
• 47. Avula SK, Khan A, Rehman NU et al. Synthesis of 1H-1,2,3-triazole derivatives as new α-glucosidase inhibitors and their molecular docking studies. Bioorg. Chem. 81, 98–106 (2018).
  Medline CASGoogle Scholar
• 48. Gong Z, Peng Y, Qiu J, Cao A, Wang G, Peng Z et al. Synthesis, in vitro α-glucosidase inhibitory activity and molecular docking studies of novel benzothiazole-triazole derivatives. Molecules 22, 1555 (2017). • References 46–48 describe studies of 1,2,3-triazole-containing molecular hybrids for α-glucosidase inhibition.
  Google Scholar
• 49. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care 32(Suppl. 2), S232–S236 (2009).
  Medline CASGoogle Scholar
• 50. Avupatia VR, Yejella RP, Akula A et al. Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents. Bioorg. Med. Chem. Lett. 22, 6442–6450 (2012).
  MedlineGoogle Scholar
• 51. Luo Y, Ma L, Zheng H et al. Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J. Med. Chem. 53, 273–281 (2010).
  Medline CASGoogle Scholar
• 52. Xia Z, Knaak C, Ma J et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 52, 74–86 (2009).
  Medline CASGoogle Scholar
• 53. Dong HQ, Li M, Zhu F, Liu FL, Huang JB. Inhibitory potential of trilobatin from Lithocarpus polystachyus Rehd against α-glucosidase and α-amylase linked to type 2 diabetes. Food Chem. 130, 261–266 (2012). • In vitro α-glucosidase inhibition assay.
  CASGoogle Scholar
• 54. Ding SM, Lan T, Ye GJ et al. Novel oxazolxanthone derivatives as a new type of α-glucosidase inhibitor: synthesis, activities, inhibitory modes and synergetic effect. Bioorg. Med. Chem. 26, 3370–3378 (2018). • Describes the inhibition kinetic studies.
  Medline CASGoogle Scholar
• 55. Sharma R, Bali A, Chaudhari BB. Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect. Bioorg. Med. Chem. Lett. 27, 3007–3013 (2017). • Contains the methodology used for antioxidant potential evaluation of synthesized hybrids.
  Medline CASGoogle Scholar
• 56. Dallal MMS, Validi M, Douraghi M, Mehrabadi JF, Lormohammadi L. Evaluation the cytotoxic effect of cytotoxin-producing Klebsiella oxytoca isolates on the HEp-2 cell line by MTT assay. Microb. Pathog. 113, 416–420 (2017). • Describes the MTT assay used to determine the cell toxicity of compounds.
  MedlineGoogle Scholar
• 57. Kato A, Hayashi E, Miyauchi S et al. α-1-C-Butyl-1,4-dideoxy-1,4-imino-L-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia. J. Med. Chem. 55, 10347–10362 (2012). • The in vivo disaccharide loading test was performed as per the procedure described in this article.
  Medline CASGoogle Scholar
• 58. Källberg M, Wang H, Wang S et al. Template-based protein structure modeling using the RaptorX web server. Nat. Protoc. 7, 1511–1522 (2012). • Homology model-building of the α-glucosidase enzyme.
  Medline CASGoogle Scholar
• 59. Benkert P, Tosatto SC, Schomburg D. QMEAN: a comprehensive scoring function for model quality assessment. Proteins 71, 261–277 (2008).
  Medline CASGoogle Scholar
• 60. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407–410 (2007). • References 59 and 60 describe validation of the homology model.
  MedlineGoogle Scholar
• 61. Friesner RA, Banks JL, Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739–1749 (2004).
  Medline CASGoogle Scholar
• 62. Halgren TA, Murphy RB, Friesner RA et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750–1759 (2004).
  Medline CASGoogle Scholar
• 63. Friesner RA, Murphy RB, Repasky MP et al. Mainz, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J. Med. Chem. 49, 6177–6196 (2006). • References 61–63 describe molecular docking simulation studies.
  Medline CASGoogle Scholar
• 64. Yang KY, Shen Y, Liu H, Yao X. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38a MAP kinase. J. Chem. Inf. Model. 51, 3235–3246 (2011). • Binding free energy calculations to determine ligand strain energies and ligand-binding energies for a set of ligands and α-glucosidase.
  Medline CASGoogle Scholar
• 65. Schrödinger, Inc. QikProp, V5.2., Schrödinger Suite 2019. https://www.schrodinger.com/qikprop. • ADME predictive studies of synthesized hybrids.
  Google Scholar
• 66. Ahr HJ, Boberg M, Krause HP et al. Pharmacokinetics of acarbose. Part I: absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittelforschung 39, 1254–1260 (1989). • Pharmacokinetics of the clinically used α-glucosidase inhibitor acarbose.
  Medline CASGoogle Scholar